Oruka Therapeutics, Inc. (ORKA) stock
ORKANasdaqPharmaceutical PreparationsFiscal year ends December 31
$96.32−2.92 (-2.94%)
Close on Nov 17, 2026Market cap $6.38BP/E –Yield –
Oruka Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Oruka Therapeutics's ebitda for the twelve months ending Jun 30, 2024 was -$27.49M. For fiscal 2023 it was -$7.28M. The highest annual figure on record is -$4.28M in fiscal 2012.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | -$7.28M | – |
| FY2022 | Dec 31, 2022 | -$10.58M | – |
| FY2021 | Dec 31, 2021 | -$19.32M | – |
| FY2020 | Dec 31, 2020 | -$9.76M | – |
| FY2019 | Dec 31, 2019 | -$5.80M | – |
| FY2018 | Dec 31, 2018 | -$8.10M | – |
| FY2017 | Dec 31, 2017 | -$18.69M | – |
| FY2016 | Dec 31, 2016 | -$16.59M | – |
| FY2015 | Dec 31, 2015 | -$11.44M | – |
| FY2014 | Dec 31, 2014 | -$9.68M | – |
| FY2013 | Dec 31, 2013 | -$6.91M | – |
| FY2012 | Dec 31, 2012 | -$4.28M | – |
| FY2011 | Dec 31, 2011 | -$6.76M | – |
| FY2010 | Dec 31, 2010 | -$8.84M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2024 | Jun 30, 2024 | -$21.49M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.48M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.59M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.93M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.97M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.79M | – |
| Q4 FY2022 | Dec 31, 2022 | -$1.54M | – |
| Q3 FY2022 | Sep 30, 2022 | -$2.55M | – |
| Q2 FY2022 | Jun 30, 2022 | -$3.21M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.27M | – |
| Q4 FY2021 | Dec 31, 2021 | -$5.68M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.71M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.83M | – |
| Q1 FY2021 | Mar 31, 2021 | -$4.10M | – |
| Q4 FY2020 | Dec 31, 2020 | -$5.12M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.34M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.28M | – |
| Q3 FY2019 | Sep 30, 2019 | -$1.24M | – |
| Q2 FY2019 | Jun 30, 2019 | -$1.50M | – |
| Q1 FY2019 | Mar 31, 2019 | -$1.78M | – |
| Q4 FY2018 | Dec 31, 2018 | -$1.52M | – |
| Q3 FY2018 | Sep 30, 2018 | -$1.66M | – |
| Q2 FY2018 | Jun 30, 2018 | -$2.15M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.77M | – |
| Q4 FY2017 | Dec 31, 2017 | -$4.29M | – |
| Q3 FY2017 | Sep 30, 2017 | -$4.47M | – |
| Q2 FY2017 | Jun 30, 2017 | -$5.55M | – |
| Q1 FY2017 | Mar 31, 2017 | -$4.37M | – |
| Q4 FY2016 | Dec 31, 2016 | -$4.29M | – |
| Q3 FY2016 | Sep 30, 2016 | -$4.70M | – |
| Q2 FY2016 | Jun 30, 2016 | -$3.94M | – |
See a number that looks wrong?